Company intelligence / Profile preview

Angelini Ventures

Rome, Lazio, Italyangeliniventures.com ↗

Ownership: Private
Development stage: Other

Overview

Angelini Ventures has invested approximately €100 million into 21 companies across biotech and digital health sectors. Its investments support programs ranging from preclinical research to Phase 1b clinical trials. Notable results include advancing antisense therapies for neurological conditions and immunotherapies targeting fibrin in neurodegenerative diseases.

Therapeutic areas: OtherPsychiatryOphthalmologyNeurology
Modalities: Small moleculeAntibodyRNA therapyAntisense oligonucleotideImmunotherapy
Industry: Investors

Partnerships

Apollo Health VenturesSV Health Investors' Biotech FundDementia Discovery FundDolby Family VenturesEli Lilly and Company’s MRL Venture Fund/Sanofi VenturesBayern Kapital

Beyond the preview

Go deeper on Angelini Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angelini Ventures.

Explore the full profile